Scholarlink

Introduction <p>Migraine is a chronic, disabling neurological disorder affecting the Japanese population, with a significant impact on quality of life and daily activities. Lasmiditan, a selective 5-HT<sub>1F</sub> receptor agonist approved for acute migraine treatment, provides an alternative for patients who cannot tolerate or do not respond to existing therapies, including triptans. The study aimed to evaluate the real-world safety and effectiveness of lasmiditan in Japanese patients with migraine as part of post-marketing pharmacovigilance requirements.</p> Methods <p>This single-arm, multicenter, non-interventional, prospective observational study enrolled 550 patients from 53 medical sites across Japan. Patients newly prescribed lasmiditan for acute migraine between June 2022 and September 2024 were included. Data were collected via electronic case report forms, eDiaries, and questionnaires. Safety assessments included adverse events (AEs), serious AEs (SAEs), and treatment-emergent AEs (TEAEs). Effectiveness was evaluated by pain freedom and pain relief at 2&#xa0;h post-dose. Data were summarized using descriptive statistics.</p> Results <p>Of the 400 patients analyzed for safety (mean age 40.5&#xa0;years; 79.5% female), 56.0% received 50&#xa0;mg and 42.8% received 100&#xa0;mg lasmiditan as the initial dose. About 41.8% experienced at least one TEAE, with no SAEs or deaths. The most common TEAEs were dizziness (8.4%) and somnolence (3.9%) with a median time to resolution of 3 and 4&#xa0;h, respectively. In the effectiveness analysis set (<i>n</i> = 328), for moderate-to-severe headache, 21.5% and 53.9% achieved pain freedom or pain relief, respectively, 2&#xa0;h post-first dose. For specific daily activities, 45.9% of work or school tasks improved from “severely disturbed” and “couldn’t move” to “no problem” or “slightly disturbed” after 2&#xa0;h.</p> Conclusions <p>Lasmiditan was associated with a manageable safety profile and effectiveness in patients with acute migraine in routine clinical practice in Japan, with no new safety concerns identified.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-World Safety and Effectiveness of Lasmiditan in Patients with Migraine: A Post-Marketing Observational Study in Japan

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月23日

查看全文
  • Naoko Sanno,
  • Kevin Y. Urayama,
  • Joji Mori,
  • Kenichi Yoshizawa,
  • Chie Hashimoto

摘要

Introduction

Migraine is a chronic, disabling neurological disorder affecting the Japanese population, with a significant impact on quality of life and daily activities. Lasmiditan, a selective 5-HT1F receptor agonist approved for acute migraine treatment, provides an alternative for patients who cannot tolerate or do not respond to existing therapies, including triptans. The study aimed to evaluate the real-world safety and effectiveness of lasmiditan in Japanese patients with migraine as part of post-marketing pharmacovigilance requirements.

Methods

This single-arm, multicenter, non-interventional, prospective observational study enrolled 550 patients from 53 medical sites across Japan. Patients newly prescribed lasmiditan for acute migraine between June 2022 and September 2024 were included. Data were collected via electronic case report forms, eDiaries, and questionnaires. Safety assessments included adverse events (AEs), serious AEs (SAEs), and treatment-emergent AEs (TEAEs). Effectiveness was evaluated by pain freedom and pain relief at 2 h post-dose. Data were summarized using descriptive statistics.

Results

Of the 400 patients analyzed for safety (mean age 40.5 years; 79.5% female), 56.0% received 50 mg and 42.8% received 100 mg lasmiditan as the initial dose. About 41.8% experienced at least one TEAE, with no SAEs or deaths. The most common TEAEs were dizziness (8.4%) and somnolence (3.9%) with a median time to resolution of 3 and 4 h, respectively. In the effectiveness analysis set (n = 328), for moderate-to-severe headache, 21.5% and 53.9% achieved pain freedom or pain relief, respectively, 2 h post-first dose. For specific daily activities, 45.9% of work or school tasks improved from “severely disturbed” and “couldn’t move” to “no problem” or “slightly disturbed” after 2 h.

Conclusions

Lasmiditan was associated with a manageable safety profile and effectiveness in patients with acute migraine in routine clinical practice in Japan, with no new safety concerns identified.